<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> is a major barrier to achieving glycemic goals in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Both <z:hpo ids='HP_0011009'>acute</z:hpo> and chronically recurrent hypoglycemic events appear to have long-term consequences for patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="2" pm="."><plain>Chronically <z:hpo ids='HP_0001988'>recurrent hypoglycemia</z:hpo> may lead to an impairment of the counterregulatory system, with the potential for the development of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness syndrome, increased severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>-associated hospitalization, and increased mortality </plain></SENT>
<SENT sid="3" pm="."><plain>Hypoglycemic events may also have negative implications in <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and/or <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Avoidance of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> by treating with appropriate, individualized regimens for patients with T2DM should be a primary focus of physicians </plain></SENT>
<SENT sid="5" pm="."><plain>Utilizing traditional agents (eg, <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>) that do not promote <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, in combination with newer agents such as dipeptidyl peptidase-4 inhibitors and incretin mimetics, could offer a therapeutic advantage when trying to help patients reach their <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A(1c) goal without the added risk of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
</text></document>